ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v9i5.458ppharm-291Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESСРАВНИТЕЛЬНОЕ ИССЛЕДОВАНИЕ IN VITRO ЭКВИВАЛЕНТНОСТИ ДВУХКОМПОНЕНТНЫХ ДОЗИРОВАННЫХ АЭРОЗОЛЬНЫХ ИНГАЛЯТОРОВ С ПОМОЩЬЮ ИМПАКТОРА НОВОГО ПОКОЛЕНИЯCOMPARATIVE ANALYSIS OF THE IN VITRO EQUIVALENCE OF METERED AEROSOL INHALERS CONDUCTED BY THE NEW GENERATION IMPACTORТрухачеваЛ. А.TrukhachevaL. A.
кандидат фармацевтических наук, доцент кафедры фармацевтической и токсикологической химии Первого МГМУ им. И.М.Сеченова
neonatepearl@yandex.ruГорпинченкоН. В.GorpinchenkoN. V.neonatepearl@yandex.ruДементьевС. П.DementyevS. P.neonatepearl@yandex.ruПервый Московский государственный медицинский университет им. И.М. Сеченова, Российская ФедерацияРоссияSechenov First Moscow State Medical University, Russian FederationRussian Federation20120510201295Педиатрическая фармакология7074Copyright © Трухачева Л.А., Горпинченко Н.В., Дементьев С.П., 20122012Трухачева Л.А., Горпинченко Н.В., Дементьев С.П.Trukhacheva L.A., Gorpinchenko N.V., Dementyev S.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/291флутиказонсалметеролаэродинамическое распределение частицимпактор нового поколенияэквивалентностьдженерикиfluticasonesalmeterolaerodynamic particle size distributionnext generation impactorequivalencegeneric productsReferencesФедеральный закон Российской Федерации от 12 апреля 2010 г. № 61-ФЗ «Об обращении лекарственных средств».Федеральный закон Российской Федерации от 12 апреля 2010 г. № 61-ФЗ «Об обращении лекарственных средств».ЕМЕА, The rules governing medicinal products in the European Union. Investigation of Bioavailability and Bioequivalence. 1998; 3С: 231–244.ЕМЕА, The rules governing medicinal products in the European Union. Investigation of Bioavailability and Bioequivalence. 1998; 3С: 231–244.WorldHealth Organization, 1996, WHO Expert Expert Committee on Specifications for Pharmaceutical Preparations: thirty-fourth report. WHO Technical Report Series No. 863, Geneva. 1996. Р. 114–154.WorldHealth Organization, 1996, WHO Expert Expert Committee on Specifications for Pharmaceutical Preparations: thirty-fourth report. WHO Technical Report Series No. 863, Geneva. 1996. Р. 114–154.European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP): Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for treatment of asthma in children and adolescents. January 22, 2009. Available at: http://www.emea.europa.eu/pdfs/human/ewp/415100enfin.pdfEuropean Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP): Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for treatment of asthma in children and adolescents. January 22, 2009. Available at: http://www.emea.europa.eu/pdfs/human/ewp/415100enfin.pdfHealth Canada: Guidance to establish equivalent or relative potency of safety and efficacy of a second entry short-acting eta2-ago nist metered dose inhaler (April 1999). Available at: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applicdemande/guide-ld/inhal-aerosol/mdi_bad-eng.php (Accessed August 3, 2011).Health Canada: Guidance to establish equivalent or relative potency of safety and efficacy of a second entry short-acting eta2-ago nist metered dose inhaler (April 1999). Available at: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applicdemande/guide-ld/inhal-aerosol/mdi_bad-eng.php (Accessed August 3, 2011).Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir. Med. 1997; 91: 22–28.Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir. Med. 1997; 91: 22–28.Johnson M. The pharmacology of salmeterol. Life Sciences. 1993; 52: 2131–2143.Johnson M. The pharmacology of salmeterol. Life Sciences. 1993; 52: 2131–2143.Elkout H. A retrospective observational study comparing rescue medication use in children on combined versus separate long-acting beta-agonists and corticosteroids. Arch. Dis. Child. 2010; 95 (10): 817–821.Elkout H. A retrospective observational study comparing rescue medication use in children on combined versus separate long-acting beta-agonists and corticosteroids. Arch. Dis. Child. 2010; 95 (10): 817–821.Marple V., Roberts D., Romay F. Design of the next generation pharmaceutical impactor. Drug Delivery to the Lungs. 2000, 11, 127–130.Marple V., Roberts D., Romay F. Design of the next generation pharmaceutical impactor. Drug Delivery to the Lungs. 2000, 11, 127–130.European Pharmacopoeia 5.0: Chapter 2.9.18. Preparations for inhalation: Aerodynamic assessment of fine particles. 11. United States Pharmacopiea: General Chapter < 601 > Aerosols, nasal sprays, metered dose inhalers and dry powder inhalers. USP. 34: 218.European Pharmacopoeia 5.0: Chapter 2.9.18. Preparations for inhalation: Aerodynamic assessment of fine particles. 11. United States Pharmacopiea: General Chapter < 601 > Aerosols, nasal sprays, metered dose inhalers and dry powder inhalers. USP. 34: 218.Weda M., Geuns E., Vermeer R., Buiten N. et al. Equivalence testing and equivalence limits of metered dose inhalers and dry powder inhalers measured by in vitro impaction. Eur. J. Pharm. Biopharm. 2000; 49: 295–302.Weda M., Geuns E., Vermeer R., Buiten N. et al. Equivalence testing and equivalence limits of metered dose inhalers and dry powder inhalers measured by in vitro impaction. Eur. J. Pharm. Biopharm. 2000; 49: 295–302.Smyth H., Beck V., Williams D., Hickey A. The Influence of formulation and spacer device on the in vitro performance of solution chlorofluorocarbon-free propellant-driven metered dose inhalers. AAPS PharmSciTech. 2004; 5 (1): 235–241.Smyth H., Beck V., Williams D., Hickey A. The Influence of formulation and spacer device on the in vitro performance of solution chlorofluorocarbon-free propellant-driven metered dose inhalers. AAPS PharmSciTech. 2004; 5 (1): 235–241.
The authors declare that there are no conflicts of interest present.